In this video, Sarah DiGeronimo, NP, and Sydney Smith, PharmD, both from Dana-Farber Cancer Institute, Boston, Massachusetts, discuss tips for the management of common side effects resulting from the treatment of metastatic breast cancer. Some side effects discussed include nausea, neuropathy, and cancer-related fatigue.
More Videos in Metastatic Breast Cancer Content Hub
In this video, Frédérique Penault-Llorca, MD, PhD, professor of pathology, University of Clermont-Ferrandand, France, and Aditya Bardia, MD, MPH, director of translational research integration, UCLA, discuss the current…
Barbara Pistilli, MD, chair of the breast cancer unit, Gustave Roussy, Villejuif, France, provides a case-based discussion of therapeutic options for a patient with pretreated HR+/HER2- (IHC 0)…
This webinar, focused on challenging cases in metastatic breast cancer, was moderated by Ashkan Lashkari, MD, oncologist at Wellness Oncology, California, and included expert panelists Rebecca A. Shatsky,…
Exercise during curative chemotherapy for breast cancer has proven benefits. It helps reduce fatigue, preserve muscle strength, improve fitness, and enhance overall quality of life. Staying physically active…
Lobular breast cancer presents unique challenges in detection and treatment due to its diffuse growth pattern and differences from ductal cancers. Liz O’Riordan, MD, shares her personal journey,…
Part 3 – Case Discussion & Wrap-up Gabriel N. Mannis, MD, presents the case of patient “J.A.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and…
Aditya Bardia, MD, MPH, director of translational research integration, UCLA, explains how metastatic estrogen receptor-positive breast cancers can develop ESR1 mutations. Donald McDonnell, PhD, research scientist, Duke University,…
Part 1 – Case Presentation Gabriel N. Mannis, MD, presents the case of patient “J.A.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Daniel A.…
Javier Cortés, MD, PhD, head of the International Breast Cancer Centre (IBCC), Barcelona, Spain, reviews subgroup analyses from the Phase 3 EMERALD trial. Professor Cortés discusses how these…
